| Steven Ginsberg, MD | |
|
1 Robert Wood Johnson Pl, New Brunswick, NJ 08901-1928 | |
| (732) 937-8841 | |
| (732) 418-8492 |
| Full Name | Steven Ginsberg |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 39 Years |
| Location | 1 Robert Wood Johnson Pl, New Brunswick, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205918059 | NPI | - | NPPES |
| 5212006 | Medicaid | NJ | |
| 050058513 | Other | NJ | RR MCR PTAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 25MA05795500 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Morristown Medical Center | Morristown, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Associates Of Morristown Pa | 7315906591 | 132 |
News Archive
Cyberonics, Inc. has announced that study sites are being recruited for two new Phase IV epilepsy studies and that three epilepsy educational symposia have been scheduled.
Bionik Laboratories Corp., a medical device and robotics company with a core focus in robotic exoskeleton technology for users with mobility impairments, announced today that it has completed an additional sale to qualified accredited investors of units consisting of its common stock and warrants for aggregate gross proceeds of approximately US$1.4 million in a private placement transaction.
Individuals with Down syndrome are at a much greater risk of developing Alzheimer's disease, with inflammation of the brain starting early in life and the risk of Alzheimer's reaching nearly 80% by the age of 60.
Researchers from Valencia (Spain), London (England) and Sul (Brazil) have performed research to develop adhesive materials that will prevent white stains from appearing on the teeth of people who use brackets.
At the Institut Curie, CNRS and Inserm researchers have shown that cysteamine, which is already used to treat a rare disease called cystinosis, prevents the death of neurons in Huntington's disease. Like Alzheimer's and Parkinson's, Huntington's disease, is characterized by the abnormal death of neurons.
› Verified 5 days ago
| Entity Name | New Jersey Healthcare Specialists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174585780 PECOS PAC ID: 2668385253 Enrollment ID: O20031110000555 |
News Archive
Cyberonics, Inc. has announced that study sites are being recruited for two new Phase IV epilepsy studies and that three epilepsy educational symposia have been scheduled.
Bionik Laboratories Corp., a medical device and robotics company with a core focus in robotic exoskeleton technology for users with mobility impairments, announced today that it has completed an additional sale to qualified accredited investors of units consisting of its common stock and warrants for aggregate gross proceeds of approximately US$1.4 million in a private placement transaction.
Individuals with Down syndrome are at a much greater risk of developing Alzheimer's disease, with inflammation of the brain starting early in life and the risk of Alzheimer's reaching nearly 80% by the age of 60.
Researchers from Valencia (Spain), London (England) and Sul (Brazil) have performed research to develop adhesive materials that will prevent white stains from appearing on the teeth of people who use brackets.
At the Institut Curie, CNRS and Inserm researchers have shown that cysteamine, which is already used to treat a rare disease called cystinosis, prevents the death of neurons in Huntington's disease. Like Alzheimer's and Parkinson's, Huntington's disease, is characterized by the abnormal death of neurons.
› Verified 5 days ago
| Entity Name | Rutgers Health-rwj Anesthesiology Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861414989 PECOS PAC ID: 2264346493 Enrollment ID: O20031113000072 |
News Archive
Cyberonics, Inc. has announced that study sites are being recruited for two new Phase IV epilepsy studies and that three epilepsy educational symposia have been scheduled.
Bionik Laboratories Corp., a medical device and robotics company with a core focus in robotic exoskeleton technology for users with mobility impairments, announced today that it has completed an additional sale to qualified accredited investors of units consisting of its common stock and warrants for aggregate gross proceeds of approximately US$1.4 million in a private placement transaction.
Individuals with Down syndrome are at a much greater risk of developing Alzheimer's disease, with inflammation of the brain starting early in life and the risk of Alzheimer's reaching nearly 80% by the age of 60.
Researchers from Valencia (Spain), London (England) and Sul (Brazil) have performed research to develop adhesive materials that will prevent white stains from appearing on the teeth of people who use brackets.
At the Institut Curie, CNRS and Inserm researchers have shown that cysteamine, which is already used to treat a rare disease called cystinosis, prevents the death of neurons in Huntington's disease. Like Alzheimer's and Parkinson's, Huntington's disease, is characterized by the abnormal death of neurons.
› Verified 5 days ago
| Entity Name | Anesthesia Associates Of Morristown Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922057678 PECOS PAC ID: 7315906591 Enrollment ID: O20041004000993 |
News Archive
Cyberonics, Inc. has announced that study sites are being recruited for two new Phase IV epilepsy studies and that three epilepsy educational symposia have been scheduled.
Bionik Laboratories Corp., a medical device and robotics company with a core focus in robotic exoskeleton technology for users with mobility impairments, announced today that it has completed an additional sale to qualified accredited investors of units consisting of its common stock and warrants for aggregate gross proceeds of approximately US$1.4 million in a private placement transaction.
Individuals with Down syndrome are at a much greater risk of developing Alzheimer's disease, with inflammation of the brain starting early in life and the risk of Alzheimer's reaching nearly 80% by the age of 60.
Researchers from Valencia (Spain), London (England) and Sul (Brazil) have performed research to develop adhesive materials that will prevent white stains from appearing on the teeth of people who use brackets.
At the Institut Curie, CNRS and Inserm researchers have shown that cysteamine, which is already used to treat a rare disease called cystinosis, prevents the death of neurons in Huntington's disease. Like Alzheimer's and Parkinson's, Huntington's disease, is characterized by the abnormal death of neurons.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Steven Ginsberg, MD 66 W Gilbert St, 2nd Floor, Tinton Falls, NJ 07701-4947 Ph: (732) 212-0051 | Steven Ginsberg, MD 1 Robert Wood Johnson Pl, New Brunswick, NJ 08901-1928 Ph: (732) 937-8841 |
News Archive
Cyberonics, Inc. has announced that study sites are being recruited for two new Phase IV epilepsy studies and that three epilepsy educational symposia have been scheduled.
Bionik Laboratories Corp., a medical device and robotics company with a core focus in robotic exoskeleton technology for users with mobility impairments, announced today that it has completed an additional sale to qualified accredited investors of units consisting of its common stock and warrants for aggregate gross proceeds of approximately US$1.4 million in a private placement transaction.
Individuals with Down syndrome are at a much greater risk of developing Alzheimer's disease, with inflammation of the brain starting early in life and the risk of Alzheimer's reaching nearly 80% by the age of 60.
Researchers from Valencia (Spain), London (England) and Sul (Brazil) have performed research to develop adhesive materials that will prevent white stains from appearing on the teeth of people who use brackets.
At the Institut Curie, CNRS and Inserm researchers have shown that cysteamine, which is already used to treat a rare disease called cystinosis, prevents the death of neurons in Huntington's disease. Like Alzheimer's and Parkinson's, Huntington's disease, is characterized by the abnormal death of neurons.
› Verified 5 days ago
Shaul Cohen, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1 Robert Wood Johnson Pl, New Brunswick, NJ 08901 Phone: 732-937-8841 Fax: 732-418-8492 | |
James Tse, MD, PHD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1 Robert Wood Johnson Pl, New Brunswick, NJ 08901 Phone: 732-937-8841 Fax: 732-418-8492 | |
Christine Fratzola, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1 Robert Wood Johnson Pl, New Brunswick, NJ 08901 Phone: 732-937-8841 | |
Boris M Veksler, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 125 Paterson St # 3100, New Brunswick, NJ 08901 Phone: 917-497-7156 | |
Dr. Benjamin Robert Landgraf, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1 Robert Wood Johnson Pl, New Brunswick, NJ 08901 Phone: 732-937-8841 Fax: 732-418-8492 | |
Thomas Jan, M.D,/M.P.H Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 125 Paterson St, Cab 3100, New Brunswick, NJ 08901 Phone: 347-770-0003 | |
Dennis B Hall, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1 Robert Wood Johnson Pl, New Brunswick, NJ 08901 Phone: 732-937-8841 Fax: 732-418-8492 |